{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:35:06Z","timestamp":1792118106132,"version":"4.4.0"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA258621"],"award-info":[{"award-number":["R01 CA258621"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jconrel.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T21:56:38Z","timestamp":1728770198000},"page":"215-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Recent advances in targeted drug delivery systems for multiple myeloma"],"prefix":"10.1016","volume":"376","author":[{"given":"Ashruti","family":"Pant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayushi","family":"Laliwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Mohs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.10.003_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0015","series-title":"Surveillance, Epidemiology, and End Results Program","author":"National cancer institute","year":"2024"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0020","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0025","series-title":"Key Statistics about Multiple Myeloma","year":"2024"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0035","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0040","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2017.03.010","article-title":"Immunologic approaches for the treatment of multiple myeloma","volume":"55","author":"Rasche","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0060","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.3390\/ijms20215326","article-title":"Chemical patterns of proteasome inhibitors: lessons learned from two decades of drug design","volume":"20","author":"Guedes","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2012.05.013","article-title":"The big picture on nanomedicine: the state of investigational and approved nanomedicine products","volume":"9","author":"Etheridge","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: challenges encountered and future options for better treatment","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0075","series-title":"Secura Bio Announces U.S. Withdrawal of FARYDAK \u00ae (panobinostat) NDA","author":"I. SOURCE Secura Bio","year":"2021"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0080","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0085","first-page":"380","article-title":"T recent advances of FDA-approved CAR-T therapies in multiple myeloma, highlights in science","volume":"8","author":"Zhang","year":"2022","journal-title":"Eng. Technol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0090","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0100","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0105","article-title":"Real-world use of belantamab mafodotin in relapsed\/refractory multiple myeloma: a systematic review","volume":"1","author":"Nanah","year":"2023","journal-title":"JAPA Acad. J."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0110","doi-asserted-by":"crossref","first-page":"439572","DOI":"10.1200\/JCO.2024.42.36_suppl.439572","article-title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Mateos","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0115","year":"2024","journal-title":"GSK Website"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors \u2013 molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030154","article-title":"Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice","volume":"10","author":"Wang","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0135","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0140","article-title":"Development and characterization of liposomal formulation of bortezomib","volume":"1","author":"Deshantri","year":"2019","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0160","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.biomac.9b01790","article-title":"A6 peptide-tagged core-disulfide-cross-linked micelles for targeted delivery of proteasome inhibitor carfilzomib to multiple myeloma in vivo","volume":"21","author":"Zhang","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0170","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood.V124.21.82.82","article-title":"Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (pts) with previously untreated multiple myeloma (MM): phase 2 study results","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0180","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpdd.470","article-title":"An open-label, phase 1 study to assess the effects of hepatic impairment on pomalidomide pharmacokinetics","volume":"8","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0195","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1078155218788706","article-title":"Incidence and management of adverse events associated with panobinostat in the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Moore","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902017000215185","article-title":"Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma","volume":"53","author":"Karri","year":"2017","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0205","series-title":"Mayo Clinic Proceedings","first-page":"899","article-title":"Thalidomide: tragic past and promising future","author":"Rajkumar","year":"2004"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0210","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00003088-200443050-00004","article-title":"Clinical pharmacokinetics of thalidomide","volume":"43","author":"Teo","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0230","article-title":"A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies","volume":"14","author":"Ho","year":"2022","journal-title":"Ther. Ad.v Med. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0235","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0240","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0245","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-021-01016-y","article-title":"Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export","volume":"60","author":"Bader","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0250","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.0505585102","article-title":"Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0255","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance \u2013 changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0265","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13346-022-01268-6","article-title":"A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma","volume":"13","author":"Metselaar","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0270","doi-asserted-by":"crossref","first-page":"2300843","DOI":"10.1002\/smtd.202300843","article-title":"An injectable thermosensitive hydrogel containing resveratrol and dexamethasone-loaded carbonated hydroxyapatite microspheres for the regeneration of osteoporotic bone defects","volume":"8","author":"Li","year":"2024","journal-title":"Small Methods"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0275","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.otc.2010.04.003","article-title":"A comprehensive review of the adverse effects of systemic corticosteroids","volume":"43","author":"Poetker","year":"2010","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830360303","article-title":"High-dose dexamethasone for refractory or relapsing multiple myeloma","volume":"36","author":"Friedenberg","year":"1991","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2141.2010.08534.x","article-title":"Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma","volume":"152","author":"Ghosh","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","article-title":"Anthracyclines in the treatment of Cancer","volume":"54","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0295","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0300","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s11671-018-2782-0","article-title":"Doxorubicin-loaded PEG-CdTe quantum dots as a smart drug delivery system for extramedullary multiple myeloma treatment","volume":"13","author":"Chen","year":"2018","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0305","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","author":"N.I.O.D.A.D.A.K.D.-D. Bethesda (MD)","year":"2012"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/13543776.17.9.1061","article-title":"Alkylating agents and cancer therapy","volume":"17","author":"Ralhan","year":"2007","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","article-title":"Molecular mechanisms of novel therapeutic approaches for multiple myeloma","volume":"2","author":"Hideshima","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0330","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.12659\/MSM.915998","article-title":"The effect of Ras homolog C\/rho-associated coiled-protein kinase (rho\/ROCK) signaling pathways on proliferation and apoptosis of human myeloma cells","volume":"25","author":"Feng","year":"2019","journal-title":"Med. Sci. Monit."},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2024.10.003_bb0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0340","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0355","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0360","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1349-7006.1998.tb00563.x","article-title":"Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues","volume":"89","author":"Noguchi","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0365","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.12870","article-title":"Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma","volume":"98","author":"de la Puente","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2011.08.004","article-title":"Expert opinion: responsive polymer nanoparticles in cancer therapy","volume":"80","author":"Liechty","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0375","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with Immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050334","article-title":"Targeted therapies for multiple myeloma","volume":"11","author":"Leow","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0385","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3762\/bjnano.11.25","article-title":"Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine","volume":"11","author":"Francia","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0395","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.2147\/IJN.S274289","article-title":"Endocytosis and organelle targeting of nanomedicines in cancer therapy","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0400","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1535-7163.MCT-15-0867","article-title":"Dual carfilzomib and doxorubicin\u2013loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma","volume":"15","author":"Ashley","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0405","doi-asserted-by":"crossref","first-page":"1904742","DOI":"10.1002\/adma.201904742","article-title":"CD44-specific A6 short peptide boosts targetability and anticancer efficacy of polymersomal epirubicin to orthotopic human multiple myeloma","volume":"31","author":"Gu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0410","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-18-1325","article-title":"A phase I\/II study of evofosfamide, a hypoxia-activated prodrug with or without bortezomib in subjects with relapsed\/refractory multiple myeloma","volume":"25","author":"Laubach","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0415","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0420","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0425","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies\u2014current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0430","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bcp.2009.12.022","article-title":"The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan","volume":"79","author":"Wickstr\u00f6m","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0435","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: a peptide\u2013drug conjugate for the treatment of multiple myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0440","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1002\/cam4.3300","article-title":"Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines","volume":"9","author":"Schepsky","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0445","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200309000-00006","article-title":"Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-pL-fluorophenylalanine ethyl ester) and P2 (L-prolyl-mL-sarcolysyl-pL-fluorophenylalanine ethyl ester): comparison with melphalan","volume":"14","author":"Gullbo","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0450","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1349-7006.2010.01826.x","article-title":"Aminopeptidase N (CD13) as a target for cancer chemotherapy","volume":"102","author":"Wickstr\u00f6m","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0455","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/10611860310001647140","article-title":"Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1","volume":"11","author":"Gullbo","year":"2003","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0460","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0465","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0475","series-title":"FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma. 2021","author":"Food","year":"2021"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0485","article-title":"The hypoxia-activated prodrug TH-302: exploiting hypoxia in cancer therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0490","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/C5QO00211G","article-title":"Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302)","volume":"2","author":"O'Connor","year":"2015","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0495","first-page":"102","article-title":"Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0500","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: first global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-022-01310-1","article-title":"Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma","volume":"18","author":"Detappe","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121913","article-title":"Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistry","volume":"292","author":"Khan","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0515","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0520","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","article-title":"Nanomedicines for the treatment of hematological malignancies","volume":"287","author":"Deshantri","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0525","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/cancers12113144","article-title":"Recent advances in nanotherapeutics for multiple myeloma","volume":"12","author":"Iannazzo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0530","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-015-1773-5","article-title":"Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma","volume":"101","author":"Kusumoto","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0535","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0540","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0545","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/jco.2009.27.15_suppl.8517","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I\/II MMRC trial","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00965-4","article-title":"In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma","volume":"13","author":"Omstead","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0555","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.2147\/IJN.S184262","article-title":"Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma","volume":"13","author":"Braham","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0560","first-page":"417","article-title":"Proteasome inhibitors in cancer therapy, nature reviews","volume":"14","author":"Manasanch","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0570","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0575","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0580","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Orciuolo","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0585","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","article-title":"Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib","volume":"88","author":"Hacihanefioglu","year":"2008","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0590","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-0043-115648","article-title":"Investigating intestinal permeability of bortezomib using a validated HPLC-UV method","volume":"69","author":"Mahmoudian","year":"2019","journal-title":"Drug. Res. (Stuttg)"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0595","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000463","article-title":"Complete tumor regression by liposomal bortezomib in a humanized mouse model of multiple myeloma","volume":"4","author":"Deshantri","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0600","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1021\/jm500352v","article-title":"Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo","volume":"57","author":"Ashley","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0605","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/02652048.2021.1876175","article-title":"Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics","volume":"38","author":"Mahmoudian","year":"2021","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0610","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2009-01-199281","article-title":"RhoA and Rac1 GTPases play major and differential roles in stromal cell\u2013derived factor-1\u2013induced cell adhesion and chemotaxis in multiple myeloma","volume":"114","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0615","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/nn305663e","article-title":"A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes","volume":"7","author":"Stefanick","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0620","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2019.08.033","article-title":"Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro","volume":"311-312","author":"Stefanick","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0625","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neo.2019.05.006","article-title":"Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo","volume":"21","author":"Opperman","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0630","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1039\/C8NR09431D","article-title":"Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity","volume":"11","author":"Stefanick","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0635","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41232-020-00113-y","article-title":"Integrins in multiple myeloma","volume":"40","author":"Hosen","year":"2020","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0640","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0645","doi-asserted-by":"crossref","first-page":"2301377","DOI":"10.1002\/advs.202301377","article-title":"Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles","volume":"10","author":"Tarab-Ravski","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0650","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid\u2013polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Guimar\u00e3es","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0655","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0660","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-023-00828-4","article-title":"E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma","volume":"13","author":"Maksimos","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0665","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","article-title":"Polymeric micelles in cancer therapy: state of the art","volume":"332","author":"Ghosh","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0670","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0675","doi-asserted-by":"crossref","first-page":"13274","DOI":"10.1021\/acsami.7b14319","article-title":"Injectable coacervate hydrogel for delivery of anticancer drug-loaded nanoparticles in vivo","volume":"10","author":"Lee","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0680","article-title":"Encapsulation of nano-bortezomib in apoptotic stem cell-derived vesicles for the treatment of multiple myeloma","volume":"2301748","author":"Cao","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0685","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jconrel.2021.08.001","article-title":"Polymeric nanomedicines targeting hematological malignancies","volume":"337","author":"Gu","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0690","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.biomaterials.2009.01.006","article-title":"Dual-drug delivery system based on hydrogel\/micelle composites","volume":"30","author":"Wei","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0695","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Z\u00f6ller","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0700","article-title":"Hyaluronic acid-based theranostic nanomedicines for targeted cancer therapy","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126633","article-title":"\u03c9-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors","volume":"29","author":"Bhuiyan","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0710","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2020.02.004","article-title":"CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice","volume":"320","author":"Zhong","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0715","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/biom10101429","article-title":"Role of glutathione in cancer: from mechanisms to therapies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0720","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0725","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines","volume":"355","author":"Ao","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0730","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-targeted nanoparticles hijack cell adhesion\u2013mediated drug resistance to target refractory myeloma cells and prolong SurvivalCAM-DR\u2013targeted nanotherapy for myeloma","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0735","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/nnm.13.212","article-title":"pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances","volume":"9","author":"Meng","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0740","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ijc.28333","article-title":"Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model","volume":"134","author":"Miyazaki","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0745","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1038\/bcj.2012.10","article-title":"Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo","volume":"2","author":"Kiziltepe","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0750","article-title":"Pegylated liposomal doxorubicin for multiple myeloma. LID - CD008915","volume":"30","author":"Z","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0755","doi-asserted-by":"crossref","first-page":"13364","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0760","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s13204-021-02010-3","article-title":"Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells","volume":"11","author":"Ye","year":"2021","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0765","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/pharmaceutics13020274","article-title":"Nanoparticles dual targeting both myeloma cells and cancer-associated fibroblasts simultaneously to improve multiple myeloma treatment","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0770","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.2147\/CMAR.S255682","article-title":"Inhibition of multiple myeloma using 5-Aza-2\u2032-deoxycytidine and bortezomib-loaded self-assembling nanoparticles","volume":"12","author":"Che","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0775","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers11020248","article-title":"Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0780","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41375-019-0540-7","article-title":"BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8(+) cytotoxic T lymphocytes against multiple myeloma: clinical applications","volume":"34","author":"Bae","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0785","doi-asserted-by":"crossref","first-page":"1807941","DOI":"10.1002\/adfm.201807941","article-title":"Bortezomib dendrimer prodrug-based nanoparticle system","volume":"29","author":"Hu","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0790","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid\u2013polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Guimar\u00e3es","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0795","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","article-title":"Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma","volume":"270","author":"de la Puente","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0800","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jbm.b.33931","article-title":"Drug release as a function of bioactivity, incubation regime, liquid, and initial load: release of bortezomib from calcium phosphate-containing silica\/collagen xerogels","volume":"106","author":"Kruppke","year":"2018","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0805","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3390\/cancers12092709","article-title":"Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells","volume":"12","author":"Nigro","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0810","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s10876-021-02191-5","article-title":"Antitumor potential of selenium nanoparticles (SeNPs) against multiple myeloma model in RPMI8226 cells","volume":"33","author":"Li","year":"2022","journal-title":"J. Clust. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109712","article-title":"Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C\/Apaf-1\/Caspase-9\/Caspase-3 signaling pathway in vitro","volume":"122","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0820","doi-asserted-by":"crossref","first-page":"17961","DOI":"10.1038\/s41598-022-22672-5","article-title":"In vitro and ex vivo anti-myeloma effects of nanocomposite As4S4\/ZnS\/Fe3O4","volume":"12","author":"Cholujova","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0825","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1039\/D2QM01009G","article-title":"Engineered mesoporous silica-based nanoparticles as smart chemotherapy nanodevice for bortezomib administration","volume":"7","author":"De Santo","year":"2023","journal-title":"Mater. Chem. Front."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0830","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1021\/acsami.2c17214","article-title":"Targeted lymphoma therapy using a gold nanoframework-based drug delivery system","volume":"15","author":"Bariana","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0835","series-title":"CD38-Targeted and Erythrocyte Membrane Camouflaged Nano-Drug Delivery System for Photothermal-Chemotherapy in Multiple Myeloma","author":"Zhang","year":"2023"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0840","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s11671-022-03707-2","article-title":"PEG@ carbon nanotubes composite as an effective nanocarrier of ixazomib for myeloma cancer therapy","volume":"17","author":"Elgamal","year":"2022","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0845","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","article-title":"PLGA-based nanoparticles as cancer drug delivery systems","volume":"15","author":"Tabatabaei Mirakabad","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0850","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1038\/srep17579","article-title":"Delivery of miR-34a by chitosan\/PLGA nanoplexes for the anticancer treatment of multiple myeloma","volume":"5","author":"Cosco","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106516","article-title":"Co-immunizing with PD-L1 induces CD8+ DCs-mediated anti-tumor immunity in multiple myeloma","volume":"84","author":"Guo","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0860","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(14)60417-7","article-title":"Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial","volume":"384","author":"Newby","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0865","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4143\/crt.2014.249","article-title":"Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors","volume":"47","author":"Oh","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0870","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2014.12.032","article-title":"Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy","volume":"200","author":"Han","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0875","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2015.01.012","article-title":"Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts","volume":"205","author":"Zhong","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0880","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acs.biomac.8b01553","article-title":"Nanogels enable efficient miRNA delivery and target gene downregulation in transfection-resistant multiple myeloma cells","volume":"20","author":"Zilkowski","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0885","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms18010120","article-title":"The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles","volume":"18","author":"Abdal Dayem","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0890","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3390\/nano12111922","article-title":"Reactive oxygen species formed by metal and metal oxide nanoparticles in physiological media—a review of reactions of importance to nanotoxicity and proposal for categorization","volume":"12","author":"Kessler","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0895","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.addr.2011.03.008","article-title":"Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery","volume":"63","author":"Kumar","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0900","first-page":"1439","article-title":"Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138\u2212 CD34\u2212 tumor stem-like cells in multiple myeloma-bearing mice","author":"Yang","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0905","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nnm.12.216","article-title":"Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma","volume":"9","author":"Yang","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0910","first-page":"3275","article-title":"Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells","volume":"10","author":"Zhang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0915","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1166\/jbn.2014.1730","article-title":"\u03b3-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model","volume":"10","author":"Yang","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0920","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nnm.12.216","article-title":"Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma","volume":"9","author":"Yang","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0925","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cellimm.2013.07.016","article-title":"Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction","volume":"284","author":"Al-Sadoon","year":"2013","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0930","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051661","article-title":"Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types","volume":"7","author":"Badr","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0935","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1039\/D1MA00639H","article-title":"Selenium nanoparticles: a review on synthesis and biomedical applications","volume":"3","author":"Bisht","year":"2022","journal-title":"Mater. Adv."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0940","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1021\/acsnano.9b09618","article-title":"Osteotropic radiolabeled nanophotosensitizer for imaging and treating multiple myeloma","volume":"14","author":"Tang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0945","first-page":"4430","article-title":"Development of an antibody-targeted nanoparticle for early detection of minimal residual disease in multiple myeloma","volume":"130","author":"Detappe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0950","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/tcr.201800038","article-title":"Carbon nanomaterials for targeted cancer therapy drugs: a critical review","volume":"19","author":"Hosnedlova","year":"2019","journal-title":"Chem. Rec."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0960","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0965","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.10.003_bb0970","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0975","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0980","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0985","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-016-0380-0","article-title":"Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies","volume":"10","author":"Sch\u00f6nfeld","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0990","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/modpathol.3880435","article-title":"Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed Syndecan-1 accumulates in fibrotic regions","volume":"14","author":"Bayer-Garner","year":"2001","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb0995","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1000","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1005","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1010","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1015","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-04-0182","article-title":"CD74 is expressed by multiple myeloma and is a promising target for therapy","volume":"10","author":"Burton","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1020","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1025","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2013drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1030","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1111\/jcmm.13870","article-title":"Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma","volume":"22","author":"Zhang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/leu.2015.216","article-title":"A unique aptamer-drug conjugate for targeted therapy of multiple myeloma","volume":"30","author":"Wen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1040","article-title":"Diagnostic application of aptamers against leukemia, multiple myeloma and lymphoma: a review","volume":"100","author":"Yousefnia","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s42003-020-01515-x","article-title":"Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum","volume":"3","author":"Tapia-Alveal","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1050","first-page":"3","article-title":"Antibody-drug conjugates: possibilities and challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1055","first-page":"7","article-title":"Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy","volume":"1","author":"Zahavi","year":"2018","journal-title":"Antib Ther."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2019.03.001","article-title":"A novel method for determining antibody-dependent cellular phagocytosis","volume":"468","author":"Kamen","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02553","article-title":"CD38-specific biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells","volume":"9","author":"Sch\u00fctze","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12026-014-8542-z","article-title":"Complement in monoclonal antibody therapy of cancer","volume":"59","author":"Rogers","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0005-2736(00)00203-0","article-title":"Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo","volume":"1466","author":"Lopes de Menezes","year":"2000","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123773","article-title":"Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators","volume":"12","author":"Debele","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1095","series-title":"Liposomes: Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers","first-page":"189","article-title":"Liposomes for specific depletion of macrophages from organs and tissues","author":"van Rooijen","year":"2010"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1100","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567365","article-title":"Opsonins and dysopsonins of nanoparticles: facts, concepts, and methodological guidelines","volume":"11","author":"Papini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1110","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1115","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","article-title":"The use of alternative strategies for enhanced nanoparticle delivery to solid tumors","volume":"121","author":"Izci","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1120","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1125","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/B:BMMD.0000031747.05317.81","article-title":"Molecular imaging applications in nanomedicine","volume":"6","author":"Li","year":"2004","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1135","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.640954","article-title":"Animal models of multiple myeloma bone disease","volume":"12","author":"Mehdi","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.jconrel.2024.10.003_bb1140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057641","article-title":"Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment","volume":"8","author":"Fryer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1145","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/480S38a","article-title":"Animal models: towards a myeloma mouse","volume":"480","author":"DeWeerdt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1150","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/sj.bjc.6604388","article-title":"Antitumour and antiangiogenic effects of Aplidin\u00ae in the 5TMM syngeneic models of multiple myeloma","volume":"98","author":"Caers","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.10.003_bb1160","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:35:24Z","timestamp":1733578524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924006667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":232,"alternative-id":["S0168365924006667"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in targeted drug delivery systems for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}